HIV-1 integrase inhibitor resistance in viraemic-treated individuals and baseline capsid diversity relevant to future lenacapavir therapy
Abstract Background Dolutegravir (DTG)-based antiretroviral therapy has been widely adopted across sub-Saharan Africa, yet resistance pathways in non-B HIV-1 subtypes remain poorly defined. As lenacapavir (LEN), a long-acting capsid inhibitor, is introduced for prevention and treatment, characterizing baseline capsid v...